<PAGE>
EXHIBIT 10.92
* CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY THE
BRACKETS, HAS BEEN OMITTED AND FILED WITH
THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24b-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
AMENDMENT NO. 3 TO ENBREL SUPPLY AGREEMENT
THIS AMENDMENT NO. 3 TO ENBREL SUPPLY AGREEMENT (this "Amendment")
is
effective as of the 26th day of March, 2003
between and among Genentech Inc., a
Delaware corporation ("Genentech"), Immunex
Corporation, a Washington
corporation and a wholly owned subsidiary
of Amgen Inc. ("Immunex").
Genentech and Immunex are parties to that certain Enbrel Supply
Agreement dated April 12, 2002, as amended
by that certain Amendment No. 1 to
Enbrel Supply Agreement dated September 20,
2002 and that certain Amendment No.
2 dated July 16, 2002 (as amended, the
"Agreement").
WHEREAS Genentech and Immunex desire to [*] which was not
previously
contemplated by the Parties;
WHEREAS the Agreement provides an adjustment mechanism to the
Purchase
Price and the Parties desire to adjust the
Purchase Price using such mechanism.
NOW, THEREFORE, for good and valuable consideration, the receipt
and
sufficiency of which are hereby
acknowledged, the Parties agree as follows:
1.
Section 1.17 is deleted in its entirety and replaced with the
following:
"Commercial Run" means a Run that [*].
2.
Section 1.58 is deleted in its entirety and replaced with the
following:
"Qualification Run" means a Run used to document t
